Evidence Hub

Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population‐Based Nested Case‐Control Study

Pharmacotherapy, 2019

Abstract

In Rotshild et al. some typographical errors were published in “Material and Methods” and “Discussion” sections. Material and Methods section Data Source The word “logistic” in the penultimate sentence should have been “logical”. The correct sentence is: . . . The CHS database system validates the diagnoses of chronic diseases and malignancies by logical checks, such as comparing diagnoses from various providers, and by direct authentication of the diagnoses of primary physicians. . . . Discussion section The word “no” should have been added between “have” and “reason” in the penultimate sentence. The correct sentence is: . . . However, we have no reason to assume the mortality rates would be differential between the exposure groups, as the study population is based on a homogeneous cohort of patients using antihypertensive drugs. We apologize for these errors. Reference 1. Rotshild V, Azoulay L, Feldhamer I, Perlman A, Muszkat M, Matok I. Calcium channel blocker use and the risk for prostate cancer: a population-based nested case-control study. Pharmacotherapy 2019;39(6):690–6. https://doi.org/10.1002/phar.2266

How strong is the evidence?

Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free